(Q78704183)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12497018%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

title

Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12497018%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

author name string

A V Kaisary

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12497018%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

P Iversen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12497018%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

C J Tyrrell

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12497018%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

K Carroll

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12497018%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

T Morris

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12497018%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

publication date

1 January 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12497018%20AND%20SRC:MED&resulttype=core&format=json

Prostate Cancer and Prostatic Diseases

16 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12497018%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12497018%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12497018%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

page(s)

196-203

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12497018%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.pcan.4500531

16 December 2019

exact match

0 references

cites work

Quality of life, sexual functioning and sex role identity after surgical orchidectomy in patients with prostatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Prostate cancer and sexual function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Single and multiple dose pharmacokinetic evaluation of flutamide in normal geriatric volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Clinical evaluation with long-term follow-up of flutamide and estramustine as initial treatment of metastatic carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Serum prostate-specific antigen: the most useful tumor marker

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Waning sexual function--the most important disease-specific distress for patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Sex or survival: trade-offs between quality and quantity of life

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Patient preferences: survival vs quality-of-life considerations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Fulminant hepatic failure associated with bicalutamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Eosinophilic lung disease induced by bicalutamide: a case report and review of the medical literature

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Flutamide Hepatotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Ocular toxicity of Anandron in patients treated for prostatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

A randomized double-blind study evaluating Anandron associated with orchiectomy in stage D prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

French multicentre trial comparing Casodex (ICI 176,334) monotherapy with castration plus nilutamide in metastatic prostate cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Nilutamide pneumonitis: a report on eight patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500531

7 January 2021